The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
Trispecific antibodies are emerging as the next wave of multispecific therapeutics, extending the success of bispecifics by simultaneously engaging three targets. More than 100 candidates are now in clinical trials, with major players such as Pfizer, Sanofi, AbbVie and Johnson & Johnson advancing programs that have shown strong early efficacy in oncology and autoimmune disease. Recent milestones include Pfizer's tilrekimig meeting its phase‑2 endpoint in atopic dermatitis and J&J's JNJ‑79635322 achieving an 86% response rate in multiple myeloma. While manufacturing complexity remains a hurdle, advances in protein engineering suggest the first approvals could arrive by 2028.
Making Labs Smarter for Scientific Breakthroughs
Lab Thread, founded by Ryan Cawood—formerly of OXGENE and WuXi—offers an integrated digital platform that merges electronic lab notebooks, LIMS, molecular biology tools, and collaboration features. The solution addresses the chronic fragmentation of lab software, promising faster experiment setup, reduced...
Top Biotech Deals in April 2026
April 2026 marked a flurry of blockbuster biotech mergers, highlighted by Sun Pharma’s $11.75 billion acquisition of Organon, giving it a foothold in women’s health across 140 countries. Eli Lilly emerged as the most active buyer, spending roughly $11.5 billion on four...
Sickle Cell Disease After Casgevy: Seven Companies to Watch in 2026
Casgevy’s $2.2 million, ex vivo CRISPR cure proved sickle cell disease can be edited at its genetic root, but its complex manufacturing and conditioning limit broad access. In response, a wave of innovators is targeting simpler, safer, and more scalable solutions—from Beam’s...
Needle-Free Diabetes Care: 6 Devices that Painlessly Monitor Blood Sugar
Needle‑free glucose monitors are moving from research labs to commercial shelves, with six innovative devices highlighted for their non‑invasive approaches. Abbott’s FreeStyle Libre remains the market leader for interstitial sensing, while newcomers such as Occuity Indigo, D‑Pocket, Light Touch Technology,...
Five Companies Pushing Biotech in Scotland
Scotland’s life‑science sector now comprises roughly 750 companies and 46,000 employees, anchored by strong university spin‑outs in Edinburgh, Glasgow and Dundee. Within this ecosystem five biotech firms are drawing attention: Cumulus Oncology’s portfolio‑driven oncology asset creation, EnteroBiotix’s microbiome‑based IBS therapy...
How Epic Bio Is Leveraging CRISPR without Cutting DNA
Epic Bio, founded by Stanford professor Stanley Qi, is developing an epigenetic editing platform called GEMS that uses the smallest known Cas protein to modulate gene expression without cutting DNA. The system can be delivered in a single viral vector...
When ADCs Meet Targeted Protein Degraders: The Emerging Field of Degrader-Antibody Conjugates
The biotech sector is exploring degrader‑antibody conjugates (DACs), a hybrid that merges antibody‑drug conjugate targeting with catalytic protein‑degradation payloads. C4 Therapeutics has expanded its partnership with Roche to co‑develop two undisclosed oncology DAC programs, while Orum Therapeutics secured $100 million to...
CAR-T Cell Therapies Going in Vivo
Ex‑vivo CAR‑T therapies have saved tens of thousands of patients, but the industry is now pivoting to in‑vivo approaches that can be administered off‑the‑shelf. Over the past year, major pharma players have poured billions into in‑vivo CAR‑T platforms, highlighted by...
Gilead’s Pipeline Strategy in 2026: A Broadening Focus Beyond HIV
Gilead Sciences is accelerating a diversification push in 2026, adding $12.6 billion of oncology and immunology assets to a portfolio still dominated by HIV drugs. The company completed three major acquisitions—Arcellx for $7.8 billion, Tubulis for $3.15 billion, and Ouro Medicines for $1.67 billion—bolstering...
AI in Single-Cell Analysis: Solving the Interpretation Gap
Single‑cell omics drives drug discovery but interpreting cell‑state annotations remains a bottleneck. Nygen Analytics introduced CyteType, an AI‑augmented platform that adds a traceable interpretation layer to existing pipelines, converting raw clusters into biologically meaningful labels. By combining marker‑gene analysis, literature...
Modified CRISPR Tool Targets Down Syndrome Mutation
Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School have engineered a modified CRISPR system that inserts the long non‑coding RNA XIST into one copy of chromosome 21, silencing the extra genetic material that causes Down syndrome. The new...
Diagonal Therapeutics’ Innovative Clustering Antibodies for Vascular Diseases
Diagonal Therapeutics is advancing a pioneering platform of clustering antibodies designed to restore vascular receptor signaling, targeting the root cause of genetic vasculopathies. Its lead candidate, DIAG723, has earned FDA Orphan Drug Designation for hereditary hemorrhagic telangiectasia (HHT) and shows...
PARP Inhibitors: A Proven Class Facing Limits
PARP inhibitors have reshaped treatment for BRCA‑mutated cancers by exploiting synthetic lethality, but their expansion beyond this niche faces hurdles. While ovarian, breast, pancreatic, and prostate indications now include PARP‑based maintenance or combination regimens, inconsistent benefits in HRD‑positive and broader...
What New Atopic Dermatitis Treatments Are in the Pipeline in 2026?
The atopic dermatitis pipeline in 2026 is dominated by next‑generation biologics and selective small molecules that aim to improve efficacy while reducing side‑effects. Connect Biopharma’s rademikibart achieved near‑complete skin clearance in a phase 3 trial, and Apogee’s extended‑half‑life zumilokibart showed durable...
Therapy for Brain Injuries in Infants Bags Funding: Is the First HIE Drug on the Way?
ReAlta Life Sciences raised $40 million to finish its phase 2 STAR trial of pegtarazimod, a first‑in‑class drug that blocks both complement C1 and neutrophil pathways to treat hypoxic‑ischemic encephalopathy (HIE) in newborns. HIE affects about 8,000 U.S. infants annually, causing 15‑20%...
Argobio: The Venture Model Building Europe’s Next Biotech Champions
Argobio, led by Thierry Laugel, raised roughly $54.5 million in 2021 to launch a venture‑builder focused on European biotech. The model has already spun out three companies—Enodia, Laigo Bio and Elkedonia—that together secured over $46.9 million in seed funding for platforms in protein degradation...
Eight Allergy Companies to Watch in 2026
The allergy‑treatment landscape is moving from symptom relief to disease‑modifying therapies, with eight biotech firms leading the charge in 2026. Allergy Therapeutics secured German approval for its short‑course Grassmuno vaccine, while Aravax bolstered its board ahead of a phase 3 launch...
Mending University and Venture Capital Relations: Is It Possible to See Eye-to-Eye?
European university spin‑outs in deep‑tech and life sciences now represent a $398 billion asset pool, but collaboration with venture capitalists remains fraught. Tech transfer offices are tasked with bridging divergent goals—academia’s focus on discovery and publications versus VCs’ demand for speed...
Can Phage Therapy Answer the Booming Antibiotic Resistance Problem?
Antibiotic‑resistant infections cause nearly 5 million deaths annually, prompting renewed interest in bacteriophage therapy. Companies such as Armata Pharmaceuticals, TechnoPhage, and Locus Biosciences have reported positive clinical milestones, including Armata’s QIDP‑designated AP‑SA02 moving toward a phase 3 trial and TechnoPhage’s phase 2b study...
Amgen Pipeline’s Next Growth Cycle: Replacing Its Old Blockbusters
Amgen posted $36.8 billion in 2025 revenue, a 10% year‑on‑year rise, but its legacy blockbusters such as Enbrel, Xgeva and Otezla are under pressure from biosimilars and U.S. pricing reforms. Growth is now being driven by cardiovascular drugs, rare‑disease assets acquired...
Top Biotech Deals in March 2026
Biotech M&A activity peaked in March 2026 with twelve announced deals, eight of which were multi‑billion‑dollar transactions. The largest was Lilly’s $7.8 billion acquisition of Centessa, adding an orexin‑receptor‑2 program for narcolepsy. Other marquee deals included Biogen’s $5.6 billion purchase of Apellis, Merck’s...
Multi-Agent AI Delivers Reliable and Scalable Insights for Single-Cell Omics
Nygen Analytics, a Lund‑based startup founded by computational genomics expert Parashar Dhapola, is deploying multi‑agent AI to streamline single‑cell omics analysis. The platform automates cell‑type annotation, handling millions of cells while reducing error rates that can misguide drug discovery. By...
Extracellular Vesicles: A Growing Pipeline Still Searching for Validation
Extracellular vesicles (EVs), once hailed as natural delivery vehicles, have generated a sizable pipeline but no approved therapeutics yet. More than 90 clinical studies are evaluating both native MSC‑derived vesicles and engineered platforms for regeneration, gene editing, and vaccines. Companies...
The Future of Cell & Gene Therapy: Key Trends to Watch
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
Nionyx Bio’s Kidney Gene Therapy Wins the 2026 BIO-Europe Spring Startup Spotlight
Nionyx Bio, led by CEO Magdalena Tyrpien, captured first place in the 2026 BIO‑Europe Spring Startup Spotlight in Lisbon. The company focuses on a proprietary adeno‑associated virus (AAV) capsid platform paired with a Kidney Atlas to deliver gene therapies for...
Portugal: Will the Life Science Sector See Upswing Amid Funding Worries?
Portugal’s life‑science sector generated €29.7 billion ($34.4 billion) in gross value added in 2024, employing over 268,000 people across 124,000 firms. The ecosystem gained visibility after hosting BIO‑Europe Spring, showcasing biotech startups, research parks like Biocant, and major deals such as BioNTech’s...
Six Biotech Companies in Berlin to Watch in 2026
Berlin’s biotech sector is gaining global traction, highlighted by six innovative firms. 3B Pharmaceuticals secured a Novartis licensing deal for its FAP‑2286 radioligand and is collaborating on an astatine‑211 candidate. Ariceum Therapeutics dosed its first patient in a phase 1/2 trial...
Next-Generation Allosteric Modulators: A Glance at the Biotech Pipeline in 2026
Allosteric modulators, which fine‑tune protein activity rather than fully activate or inhibit, are gaining traction across neurology, oncology and immunology. Recent pipeline highlights include Rapport Therapeutics’ RAP‑219 achieving a 77.8% seizure reduction in a phase 2a study, Atavistik Bio’s AKT1‑selective inhibitor...
Biotech in New Jersey, Seven Companies Leading the Charge
New Jersey remains a heavyweight pharma cluster, home to giants like Johnson & Johnson and Merck, while nurturing a growing biotech startup scene. Companies such as ArrePath, BioAegis, Celularity, Enalare, EpiBone, Inaedis and Rocket Pharmaceuticals are advancing AI‑driven antibiotics, plasma‑protein...
HaemaLogiX – Precision Immunotherapy for Multiple Myeloma
HaemaLogiX, an Australian clinical‑stage biotech, is developing precision immunotherapies for multiple myeloma by targeting novel antigens KMA and LMA that appear only on malignant plasma cells. Peer‑reviewed research validates these targets, allowing the company to spare healthy plasma cells and...
GSK’s Two-Speed Strategy: Broad Sourcing and Selective Bets
GSK has accelerated its pipeline build‑out by pairing broad early‑stage partnerships with selective, later‑stage acquisitions such as the up‑to‑$950 million purchase of 35Pharma’s pulmonary‑hypertension candidate HS235. After spinning off Haleon, the company now leans on specialty medicines—accounting for over 40% of...
Seven T Cell Engager Companies You Should Know About
T‑cell engagers are bispecific antibodies that redirect T cells to destroy cancer cells and are being explored for autoimmune disorders. Seven companies are leading the field: Adaptin Bio secured FDA IND clearance for APTN‑101 in glioblastoma; Candid Therapeutics merged with...
The Six Biotech Companies in Portugal You Should Know About in 2026
Portugal’s biotech sector is gaining momentum, highlighted by BIO‑Europe Spring in Lisbon. Six home‑grown companies—Beat Therapeutics, BSIM Therapeutics, Exogenus, Immunethep, Mondego Bio and TechnoPhage—are advancing novel therapies ranging from DDR inhibitors for pancreatic cancer to exosome‑based wound treatments and bacteriophage...
How Leyden Labs Is Revolutionizing Flu Protection with Its Intranasal Antibody Spray
Leyden Labs unveiled an intranasal antibody spray that delivers sustained protection at the nose, the primary entry point for influenza and coronaviruses. A peer‑reviewed study in Science Translational Medicine confirmed the product’s safety, tolerability, and superior infection‑prevention rates compared with...
Brain Awareness Week: Could Ongoing R&D Spur Neuroscience Breakthroughs?
Brain Awareness Week spotlights a surge in brain‑disorder prevalence and the expanding research pipeline aimed at tackling these challenges. Recent advances range from deep‑brain stimulation and FDA‑approved amyloid‑targeting antibodies to novel manufacturing of levodopa from recycled plastic. Start‑ups such as...
Promising Biotechs in Maryland Right Now
Maryland’s life‑science cluster, home to over 2,700 institutions, is projected to generate a $16.7 billion R&D market by 2026. Six home‑grown biotech firms—SciNeuro, Gain Therapeutics, Theriva Biologics, Supernus Pharmaceuticals, Elixirgen Therapeutics and Altimmune—have secured sizable financing and strategic partnerships in the...
Can Bristol Myers Squibb’s Pipeline Strategy Offset a Major Patent Cliff?
Bristol Myers Squibb faces a major patent cliff as flagship drugs like Revlimid, Pomalyst, Opdivo and Eliquis lose exclusivity, threatening its revenue base. To counteract the decline, the company is reshaping its pipeline through internal R&D and high‑profile acquisitions, emphasizing...
Six Biotech Companies Advancing the Next Generation of Prostate Cancer Therapies
Six biotech firms are pushing next‑generation prostate‑cancer therapies through late‑stage trials and financing milestones. Candel Therapeutics secured a $100 million royalty deal to fund aglatimagene’s launch, while Coherus Oncology closed a $50.1 million offering and partnered with J&J for a CCR8 antibody...
How Colorectal Cancer Treatment Is Evolving in 2026
Colorectal cancer remains a major global health burden, with over 1.9 million new cases and 900,000 deaths in 2022, placing it high on biotech priorities. Treatment has shifted from surgery‑centric approaches to a blend of refined chemotherapy backbones and biomarker‑driven targeted...
How to Optimize Your Biotech Company for Partnering, Licensing, and Business Success
Janita Good, a Fieldfisher partner with a D.Phil. in biochemistry, offers biotech leaders a roadmap for maximizing partnership and licensing value. She emphasizes initiating pharma discussions early, embedding commercialization plans into R&D, and aligning fundraising expectations with realistic exit timelines....
Cell Rejuvenation Therapy to Hit Clinic
Life Biosciences has secured FDA IND approval for ER-100, the first partial epigenetic reprogramming therapy to enter human trials. The gene‑therapy delivers OCT‑4, SOX‑2 and KLF‑4 to retinal ganglion cells via a single intravitreal injection, aiming to reset age‑related epigenetic...
Desert to Discovery: Five Hot Biotechs in Arizona
Arizona's biotech sector is booming, with $3.7 billion invested over the past seven years and a growing pipeline of innovative companies. Nectero Therapeutics secured a $96 million Series D to develop a fast‑track, breakthrough‑designated endovascular treatment for abdominal aortic aneurysms, while Humabiologics obtained...
Carbios Under Pressure: Financing Struggles, China Expansion, and a Growing Legal Dispute
Carbios, once a flagship of France’s industrial biotech, has seen its enzymatic PET recycling ambitions hampered by financing gaps, a delayed Longlaville plant and a costly reorganisation. The company’s cash fell to €72 million by mid‑2025, prompting a 40 % cut in...
Reversing Tumor Immunosuppression with Next-Gen GPCR Modulation
Kainova Therapeutics, formerly Domain Therapeutics, announced a Series B funding round to advance its next‑generation GPCR‑modulating platform aimed at reversing tumor immunosuppression. The rebrand signals a strategic shift toward a broader oncology focus, leveraging GPCR pathways that control immune cell trafficking....
Nine Companies Advancing Biotech in Philadelphia
Philadelphia’s biotech ecosystem, long known for CAR‑T breakthroughs, is diversifying into obesity, metabolic disease, gene editing, and solid‑tumor immunotherapies. Nine local companies illustrate this shift, from Alveus Therapeutics’ $197 million Series A obesity program to Cabaletta Bio’s autologous CD19 CAR‑T for autoimmune...
18 UK Biotech Companies You Should Know About
The article profiles 18 UK biotech firms spanning oncology, immunology, regenerative medicine and AI‑driven drug design, highlighting recent milestones such as Amphista’s $30 million upfront deal with BMS, Autolus’ FDA and EU approvals for obe‑cel, and Isomorphic Labs’ $600 million raise to...
Male Infertility Care to Shift Treatment Burden From Women
Infertility has long been framed as a women's issue, yet about half of cases stem from male factors. New treatments such as Igyxos' IGX12 monoclonal antibody, which enhances follicle‑stimulating hormone activity, aim to improve sperm production and reduce the physical...
Pfizer’s Strategy: How the Company Is Evolving After Its COVID Success
Pfizer’s post‑COVID strategy pivots from vaccine and antiviral sales to rebuilding growth through oncology and metabolic assets. The 2026 guidance excludes COVID revenue, projects modest 4% operational growth, and anticipates a $1.5 billion patent‑cliff hit. To offset these pressures, Pfizer completed...
Six RNAi Companies to Keep an Eye on in 2026
RNA interference (RNAi) has moved from a scientific curiosity to a fast‑growing therapeutic platform, with the global market projected to reach $1.97 billion by 2032. Six biotech firms—Aerska, ADARx, Alnylam, Arrowhead, City Therapeutics and SanegeneBio—are leading the next wave of innovation...